MedPath
NMPA Approval

Ocrelizumab Injection

国药准字SJ20250013

March 25, 2025

Drug Information

奥瑞利珠单抗注射液

罗可适

注射剂

300 mg(10 ml)/瓶

生物制品

March 25, 2025

March 24, 2030

Company Information

Applicant Company

Grenzacherstrasse 124, 4058 Basel, Switzerland

Manufacturing Company

Sandhofer Strasse 116, 68305 Mannheim, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

奥瑞利珠单抗注射液 - NMPA 批准文号 | MedPath